Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent
Moderna and Merck report that their personalized mRNA vaccine reduces melanoma recurrence or death by 42%, with FDA approval expected in 2027.
Merck
3 stories · RSS
Email me new stories on Merck
Coverage vs. odds, last two weeks
How much the press wrote about Merck each day, and what its busiest market did over the same days.
Stories
Major Pharma Firms Report Strong Cancer Drug Trial Results
Genmab, AstraZeneca, Amgen, GSK and Merck report positive late-stage trial outcomes for various cancer treatments.
Moderna CEO Sees Cancer Vaccine Working Beyond Melanoma
Stephane Bancel states the mRNA therapy targets various tumors and denies recent data leaks originated from Moderna or Merck.